Enter a keyword or phrase to search all pages in this section:


Advanced search

Archive:

Looking for a previously published document in this section?

Class 3 Drug Alert (Action Within 5 Days): ratiopharm GmbH - Desloratadine ratiopharm 5mg film-coated tablets (Teva livery) - EL (13)A/04 Rev 1

Document details:

Type: Drug Alert
Series No: EL (13)A/04 Rev 1
Audience: Healthcare professionals
Published: 26 February 2013
Format: Electronic only
Size: A4
Pages: 2
Price: Free
ISBN/ISSN:
Author:
Copyright: Crown
   

Help viewing PDFs:

DRUG ALERT

CLASS 3 MEDICINES RECALL

Action Within 5 Days


PHARMACY LEVEL RECALL

26 February 2013 EL (13)A/04 Rev 1 Our ref: 

MDR 46-12/12


Dear Healthcare Professional,

ratiopharm GmbH

Desloratadine ratiopharm 5mg film-coated tablets (Teva livery)

EU/1/11/746/006


Batch number Expiry date Pack size First distributed
009263 30 September 2014 1 x 30 15 February 2012
009264 30 September 2014 1 x 30 15 February 2012
010168 31 March 2015 1 x 30 14 June 2012
010321 31 March 2015 1 x 30 12 June 2012

Please replace the Drug Alert issued on 13 February 2013 with this revised document. Teva UK Limited has informed us that the batch numbers were expressed incorrectly on the original Alert. The table, above, has now been corrected. The company apologises for any additional inconvenience this may cause.

Teva UK Limited is recalling all remaining stock of the above batches because higher than expected levels of impurities were detected during routine stability testing. Although there are currently no concerns relating to patient safety, it is possible that impurities may exceed specification towards the end of the shelf-life.

Remaining stocks of these batches should be quarantined and returned to the original supplier for credit. For further stock enquiries please contact Teva UK Customer Liaison Team on 0800 590502.

For medical information enquiries please contact Teva UK limited by phone on 0207 5407117 or by email to medinfo@tevauk.com.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary Care Trusts are asked to forward this to relevant clinics and to General Practitioners and Community Pharmacists for information.

Yours faithfully

Alison Bunce
Pharmaceutical Assessor, DMRC

MHRA Distribution (further recipients by cascade):
Regional contacts for NHS Trusts and provider units
Chief pharmacists: England, Scotland, Wales, Northern Ireland
Prison health policy unit (DH)
Chief pharmacists:  Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special hospitals
Healthcare Commission for distribution to independent health care establishments
Primary care trusts (England)
Page last modified: 26 February 2013